|
22 Dec 2020 |
Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness
|
|
18 Dec 2020 |
New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
|
|
18 Dec 2020 |
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
|
|
18 Dec 2020 |
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
|
|
18 Dec 2020 |
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
|
|
18 Dec 2020 |
Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies
|
|
18 Dec 2020 |
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
|
|
18 Dec 2020 |
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
|
|
18 Dec 2020 |
FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
|
|
18 Dec 2020 |
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer
|
|
18 Dec 2020 |
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
|
|
18 Dec 2020 |
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
|
|
17 Dec 2020 |
Regeneron Provides Update on Odronextamab Clinical Trials in B-cell Non-Hodgkin Lymphomas
|
|
17 Dec 2020 |
Imfinzi recommended for approval in the EU by CHMP for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
|
|
16 Dec 2020 |
Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
|
|
16 Dec 2020 |
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
|
|
16 Dec 2020 |
Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study
|
|
16 Dec 2020 |
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trial
|
|
16 Dec 2020 |
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer
|
|
16 Dec 2020 |
FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
|
|
15 Dec 2020 |
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB16, Proposed Biosimilar to Prolia (Denosumab)
|
|
14 Dec 2020 |
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic Alterations
|
|
14 Dec 2020 |
Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™ Human Antibody Nasal Spray Against SARS-CoV-2 Infection
|
|
14 Dec 2020 |
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
|
|
11 Dec 2020 |
Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca
|
